Procter & Gamble Health Ltd - 500126 - Change In Name Of Registrar And Share Transfer Agent
We hereby bring to your notice that the Company has been intimated by its Registrar and Share Transfer Agent (RTA), of the change of its name from KFIN Technologies Private Limited to KFIN Technologies Limited pursuant to conversion into a Public Company with effect from 24th February 2022. Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Zeal ShahDesignation :- Company Secretary and Compliance Officer Procter & Gamble Health Ltd - 500126 - Closure of Trading Window
We would like to inform you that the Trading Window of the Company shall remain closed for Directors and designated employees from April 1, 2022 until 48 hours from the publication of the unaudited financial results for the quarter ended March 31, 2022. Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended March 31, 2022
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 ,inter alia, to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 05, 2022, inter alia, to consider and approve the unaudited financial results for the quarter ended March 31, 2022 Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agents (RTA), KFin Technologies Private Limited, regarding the loss /misplacement of the share certificate(s). We request you to take the same on record and acknowledge receipt. Procter & Gamble Health Ltd - 500126 - Related Party Transactions For Six Months Ended December 31,2021
We are enclosing herewith the Related Party Transactions for six months ended December 31,2021. Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended December 31, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige Q3FY22 Quarterly Result Announced for Procter & Gamble Health Ltd.
Pharmaceuticals firm Procter & Gamble Health declares Q3FY22 result: Sales up by 15% for quarter ended December 31, 2021 The company has recorded a total sale of Rs 273 crores for the quarter ended December 31, 2021, vs Rs 238 Crores a year ago, up by 15%. The Profit After Tax (PAT) was Rs 44.8 crores vs Rs 67.9 crores a year ago due to higher investments in marketing initiative to support growth in current year and help of one time reversals in the base period. Sales for the six-month period ending December 31, 2021, were Rs 541 crores, vs Rs 496 Crores a year ago, up by 9%. Profit After Tax for same period was Rs 100.2 Crore vs Rs 127.1 Crore a year ago Milind Thatte, Managing Director, Procter & Gamble Health Limited said, “The Company has delivered sales of Rs 273 Crores in a challenging quarter growing by 15% over year ago on the back of continued demand for our quality and affordable vitamins, minerals, and medicinal products. The pandemic has made consumers overall more cognizant of their health and wellness needs, with a growing demand for trusted brands for themselves and their families as they live in the new normal. Our teams continued to step up on category and brand building efforts through innovative scientific forums, consumer awareness and pharmacy education initiatives. The Company, in association with FOGSI (The Federation of Obstetric and Gynaecological Societies of India), achieved a new GUINNESS WORLD RECORD™ title, for its efforts on creating awareness on Iron Deficiency Anemia. The Company launched ‘P&G; Health Academy’ a new scientific education platform for Doctors, and also initiated a new sustainability initiative for Pharmacies under its flagship CSR program ‘SEHAT’ (meaning Health), among various other initiatives. We are delighted to share that SEHAT recently bagged the prestigious Gold in the ‘Best Public Health Initiative’ category at the India Health and Wellness Awards supported by Niti Aayog. With continued focus on health and safety, the Company also introduced a host of initiatives towards supporting wellness needs of our employees. The Company has made significant progress in its gender diversity efforts recording a 4x increase in the number of women in the sales hierarchy over the last 12 months,” he added. Result PDF Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended December 31, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige.
Drugmaker Merck has strong fourth quarter as Covid-19 treatment debuts
The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker's COVID-19 treatment debuted with nearly $1 billion in sales. Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday. Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion. Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street's per-share projections of $1.53, according to a survey by the data firm FactSet. Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts. The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue. Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue. Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in ear